![]() |
|
|
Vol. 292, Issue 2, 480-488, February 2000
Departments of Biochemistry and Molecular Biology (S.K.K.) and
Anatomy (P.N.N.), The University of British Columbia, Vancouver,
British Columbia, Canada; ISIS Pharmaceuticals, Carlsbad, California
(C.F.B.); and INEX Pharmaceuticals Corporation, Burnaby, British
Columbia, Canada (S.C.S., M.C.M., P.S., M.J.H.).
The anti-inflammatory activity of free and liposome-encapsulated
oligonucleotide targeted against intercellular adhesion molecule-1 mRNA
was investigated in a delayed type hypersensitivity model of acute
inflammation in mice. Contact hypersensitivity reactions to
2,4-dinitrofluorobenzene were monitored by measuring ear thickness and
cellular infiltration, both of which were observed to be maximal 24 h after ear challenge. A murine-specific phosphorothioate
oligodeoxynucleotide and various control sequences were each passively
encapsulated into 100-nm diameter large unilamellar vesicles composed
of egg phosphatidylcholine and cholesterol. All formulations were
administered as a single-bolus injection into the tail vein ~15 min
after initiating ear inflammation. Oligodeoxynucleotide dose was varied
from 5 to 50 mg/kg and the extent of inflammation was assessed 24 h later. Mice treated with free oligonucleotide, empty vesicles, or
encapsulated control sequences showed no measurable effect on ear
swelling or cellular infiltration compared with untreated controls.
However, mice that received the active sequence encapsulated in lipid
vesicles exhibited near baseline levels of ear thickness and leukocyte infiltration, similar to that observed in mice treated with a topical
corticosteroid. These data demonstrate the utility of liposome-encapsulated intercellular adhesion molecule-1 antisense oligonucleotide as a novel anti-inflammatory therapeutic.
This article has been cited by other articles:
![]() |
S. SEELIGER, C. K. DERIAN, N. VERGNOLLE, N. W. BUNNETT, R. NAWROTH, M. SCHMELZ, P.-Y. VON DER WEID, J. BUDDENKOTTE, C. SUNDERKOTTER, D. METZE, et al. Proinflammatory role of proteinase-activated receptor-2 in humans and mice during cutaneous inflammation in vivo FASEB J, October 1, 2003; 17(13): 1871 - 1885. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Mui, S. G. Raney, S. C. Semple, and M. J. Hope Immune Stimulation by a CpG-Containing Oligodeoxynucleotide Is Enhanced When Encapsulated and Delivered in Lipid Particles J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1185 - 1192. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Q. Sun, M. J. Cairns, E. G. Saravolac, A. Baker, and W. L. Gerlach Catalytic Nucleic Acids: From Lab to Applications Pharmacol. Rev., September 1, 2000; 52(3): 325 - 348. [Abstract] [Full Text] [PDF] |
||||